Originalarbeiten

Augustin M, Schoretsanitis G, Hiemke C, Gründer G, Haen E, Paulzen M. Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism. J Clin Psychiatry 2018; doi: 10.4088/JCP.17m12086. [Epub ahead of print]

Paulzen M, Stingl JC, Augustin M, Saßmannshausen H, Franz C, Gründer G, Schoretsanitis G. Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clin Pharmacokinet 2018; doi: 10.1007/s40262-018-0713-y. [Epub ahead of print]

Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C. Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie.
[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. Nervenarzt. 2018 Nov 16. doi: 10.1007/s00115-018-0643-9. [Epub ahead of print]

Schoretsanitis G, Augustin M, Saßmannshausen H, Franz C, Gründer G, Paulzen M. Antidepressants in breast milk; comparative analysis of excretion ratios. Arch Womens Ment Health 2018; doi: 10.1007/s00737-018-0905-3. [Epub ahead of print]

Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Gründer G, Paulzen M. Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol. 2018; 33(6): 322-329.

Veselinović T, Vernaleken I, Janouschek H, Cumming P, Paulzen M, Mottaghy FM, Gründer G. The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology (Berl) 2018; 235(8): 2221-2232.

Augustin M, Schoretsanitis G, Gründer G, Haen E, Paulzen M. How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. J Clin Psychopharmacol 2018; 38(5): 498-501.Psychopharmacology (Berl) 2018; 235(8): 2221-2232.

Kuzin M, Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clin Pharmacokinet 2018; 57(6): 729-737.

Paulzen M, Goecke TW, Kuzin M, Augustin M, Gründer G, Schoretsanitis G. Pregnancy exposure to quetiapine - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. Schizophr Res 2018; 195: 252-257.

Veselinović T, Vernaleken I, Cumming P, Henning U, Winkler L, Kaleta P, Paulzen M, Luckhaus C, Gründer G. Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion. Neuropsychiatr Dis Treat. 2018; 14: 1125-1138.

Paulzen M, Schoretsanitis G, Hiemke C, Gründer G, Haen E, Augustin M. Reduced clearance of venlafaxine in a combined treatment with quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 2018; 85: 116-121.

Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Laux G, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zurek G, Hiemke C. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry 2018; 19(3): 162-174.

Hoffmann S, Gründer G, Paulzen M. Mit „Therapeutischem Drug Monitoring“ Psychopharmakotherapie optimieren (CME-Artikel). Neurotransmitter 2018; 29:46-57.

Paulzen M, Haen E, Hiemke C, Fay B, Unholzer S, Gründer G, Schoretsanitis G. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. J Affect Disord 2018; 227: 506-511.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(1-02): 9-62.

Schoretsanitis G, de Leon J, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations. Eur Neuropsychopharmacol 2018; 28(1): 130-137.

Schoretsanitis G, Kirner-Veselinovic A, Gründer G, Paulzen M. Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. Aust N Z J Psychiatry 2017; 51(10): 1059-1060.

Pfeifer P, Tüscher O, Buchholz HG, Gründer G, Vernaleken I, Paulzen M, Zimmermann US, Maus S, Lieb K, Eggermann T, Fehr C, Schreckenberger M. Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. Addict Biol 2017; 22(5): 1449-1458.

Paulzen M, Haen E, Hiemke C, Stegmann B, Lammertz SE, Gründer G, Schoretsanitis G. Cytochrome P450 mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol. 2017; 83(8): 1668-1675.

Paulzen M, Goecke TW, Stingl JC, Janssen G, Stickeler E, Gründer G, Schoretsanitis G. Pregnancy exposure to citalopram - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Prog Neuropsychopharmacol Biol Psychiatry 2017; 79: 213-219.

Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M. Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism. Schizophr Res 2017; 185: 51-57.

Paulzen M, Haen E, Stegmann B, Unterecker S, Hiemke C, Gründer G, Schoretsanitis G. Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci 2017; 267(4):325-333.

Paulzen M, Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KR, Walther S, Lammertz SE, Haen E. Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2017; 76: 101-106.

Paulzen M, Goecke TW, Stickeler E, Gründer G, Schoretsanitis G. Sertraline in pregnancy - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord 2017; 212: 1-6.

Hovancakova J, Schoretsanitis G, Grözinger M, Gründer G, Paulzen M. Interaction Between Risperidone, Venlafaxine, and Metronidazole: An Unknown Thread. J Clin Psychopharmacol. 2016; 36(6): 730-733.

Paulzen M, Eap CB, Gründer G, Kuzin M. Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. J Clin Psychopharmacol 2016; 36(1): 90-2.

Paulzen M, Gründer G, Veselinovic T, Wolf B, Hiemke C, Lammertz SE. Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid. J Affect Disord 2016; 189: 159-63.

Paulzen M, Haen E, Gründer G, Lammertz SE, Stegmann B, Schruers KR, Walther S, Schoretsanitis G. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol 2016; 30(8): 803-9.

Paulzen M, Haen E, Stegmann B, Hiemke C, Gründer G, Lammertz SE, Schoretsanitis G. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology 2016; 73: 9-15.

Paulzen M, Lammertz SE, Gründer G, Veselinovic T, Hiemke C, Tauber SC. Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants: Erratum. Int Clin Psychopharmacol. 2016; 31(5): 300.

Paulzen M, Lammertz SE, Gründer G, Veselinovic T, Hiemke C, Tauber SC. Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants. Int Clin Psychopharmacol 2016; 31(3): 119-26.

Schoretsanitis G, Haen E, Gründer G, Stegmann B, Schruers KR, Hiemke C, Lammertz SE, Paulzen M. Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. J Clin Psychopharmacol. 2016; 36(6): 554-561.

Schoretsanitis G, Haen E, Hiemke C, Gründer G, Stegmann B, Schruers KR, Veselinovic T, Lammertz SE, Paulzen M. Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? Int Clin Psychopharmacol 2016; 31(5): 259-64.

Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KR, Walther S, Lammertz SE, Haen E, Paulzen M. Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol 2016; 72(9): 1091-8.

Paulzen M, Groppe S, Tauber SC, Veselinovic T, Hiemke C, Gründer G. Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry 2015; 76(1): 25-31.

Paulzen M, Gründer G, Orlikowsky T, Gräf CM, Hoeltzenbein M, Veselinovic T. Suicide Attempt During Late Pregnancy With Quetiapine: Nonfatal Outcome Despite Severe Intoxication. J Clin Psychopharmacol 2015; 35(3): 343-4.

Paulzen M, Gründer G, Tauber SC, Veselinovic T, Hiemke C, Groppe SE. Distribution pattern of mirtazapine and normirtazapine in blood and CSF. Psychopharmacology (Berl) 2015; 232(4): 807-13.

Paulzen M, Kuzin , Gründer G. Arzneimittelmetabolismus und Therapieversagen DNP - Der Neurologe und Psychiater 2015; 16 (2): 46-55.

Paulzen M, Lammertz SE, Veselinovic T, Goecke TW, Hiemke C, Gründer G. Lamotrigine in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol 2015; 30(5): 249-54

Veselinovic T, Vernaleken I, Janouschek H, Kellermann T, Paulzen M, Cumming P, Gründer G. Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology (Berl) 2015 ; 232(9): 1607-17.

Gründer G, Veselinovic T, Paulzen M. [Antidepressive agents and suicidal tendencies.] Nervenarzt 2014; 85(9): 1108-16.

Paulzen M, Henkel K, Tauber S, Reich A, Eap CB, Gründer G. Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt. J Clin Psychopharmacol 2014; 34(3): 398-9.

Paulzen M, Müller A, Akkus T, Bergmann F, Schneider F. [Integrated care for depressive disorders.] Integrierte Versorgung bei depressiven Störungen Nervenarzt 2014; 85(7): 856-64.

Paulzen M, Schneider F. [Schizophrenia and other psychotic disorders in DSM-5: summary of the changes compared to DSM-IV]. Schizophrenie und andere psychotische Störungen im DSM-5 Nervenarzt 2014; 85(5): 533-42.

Paulzen M, Veselinovic T, Gründer G. Effects of psychotropic drugs on brain plasticity in humans. Restor Neurol Neurosci 2014; 32(1): 163-81

Veselinovic T, Paulzen M, Gründer G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother 2013; 13(11): 1141-59.

Gründer G, Veselinovic T, Paulzen M. [Basic principles of therapy with neuropsychotropic drugs]. Nervenarzt 2012; 83(9): 1193-208.

Paulzen M, Tauber SC, Kirner-Veselinovic A, Gründer G. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient. J Clin Psychiatry. 2011; 72(11): 1465-7.

Paulzen M, Finkelmeyer A, Grözinger M. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. Pharmacopsychiatry 2011; 44: 317-23.

Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I. Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. Pharmacopsychiatry 2011; 44: 236-48.

Spreckelmeyer KN, Paulzen M, Raptis M, Baltus T, Schaffrath S, Van Waesberghe J, Zalewski MM, Rösch F, Vernaleken I, Schäfer WM, Gründer G. Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)f]fallypride positron emission tomography study. Biol Psychiat 2011; 70: 770-6.

Paulzen M, Orfanos S, Gründer G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry 2010; 167(3): 351-2.

Nazirizadeh Y, Vogel F, Bader W, Haen E, Pfuhlmann B, Gründer G, Paulzen M, Schwarz M, Zernig G, Hiemke C. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 2010; 66(8): 797-803.

Paulzen M, Hiemke C, Gründer G. Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. Int J Neuropsychopharmacol 2009; 12(10): 1431-1432.

Nickl-Jockschat T, Paulzen M, Schneider F, Grözinger M. Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol 2009; 32(1): 55-57.

Paulzen M, Gründer G. Toxic psychosis after intake of the hallucinogen salvinorin A. J clin psychiatr 2008; 69 (9): 1501-1502.

Paulzen M, Clement HW, Gründer G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol 2008; 11: 289-291.

Paulzen M, Gründer G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. International Journal of Neuropsychopharmacoly 2007; 10: 149-151.

Weitere Informationen zu den wissenschaftlichen Veröffentlichungen entnehmen Sie bitte der Literatur-Datenbank PubMed

Buchbeiträge